71例恶性腹腔积液腔内药物治疗疗效的回顾性分析  

Effects of drug therapy on malignant ascites: retrospective analysis of 71 cases

作　　者：陆彬彬[1] 朱娅[1] 王娟[1] 王莉[1] 王科明[1] 王朝霞[1] LU Binbin;ZHU Ya;WANG Juan;WANG Li;WANG Keming;WANG Zhaoxia(Department of Oncology,the Second Affiliated Hospital of Nanjing Medical University,Nanjing 210011,China)

机构地区：[1]南京医科大学第二附属医院肿瘤科

出　　处：《中国医药科学》2019年第24期32-35,183,共5页China Medicine And Pharmacy

基　　金：江苏省青年医学重点人才资助项目(QNRC2016662)

摘　　要：目的回顾性分析71例恶性腹腔积液的治疗效果。方法选取2012年1月~2018年12月我院收治的71例给于腔内药物灌注治疗的恶性腹腔积液患者为研究对象,采用回顾性队列分析,按治疗药物分为顺铂组和顺铂联合恩度组及氟尿嘧啶组;按治疗次数分为初治组和复发组。结果顺铂组治疗胃癌12例,ORR为50%,顺铂联合恩度组治疗胃癌14例,ORR为57.1%,两者比较差异有统计学意义(P<0.05);顺铂组治疗卵巢癌8例,ORR为62.5%,顺铂联合恩度组治疗卵巢癌5例,ORR为60%,差异无统计学意义(P>0.05);顺铂组治疗肺癌3例,ORR为0,顺铂联合恩度组治疗肺癌6例,ORR为16.7%,差异无统计学意义(P>0.05);氟尿嘧啶组治疗结直肠癌13例,ORR为15.3%,胰胆系统癌7例,ORR为0。初治组中,给予顺铂治疗9例,ORR为66.7%,顺铂联合恩度治疗12例,ORR为66.7%,差异无统计学意义(P>0.05);复治组中,给与顺铂治疗14例,ORR为35.7%,顺铂联合恩度治疗16例,ORR为31.2%,差异无统计学意义(P>0.05);在顺铂组中,初治的ORR为66.7%,复治组的ORR为35.7%,差异有统计学意义(P<0.05);在顺铂联合恩度组中,初治的ORR为66.7%,复治组的ORR为31.2%,差异无统计学意义(P>0.05)。顺铂组和顺铂联合恩度组在药物毒副反应上无统计学差异,氟尿嘧啶组药物毒副反应轻。结论顺铂依然是恶性腹腔积液腔内治疗的有效药物,尤其是对于胃癌和卵巢癌。Objective To retrospectively analyze the effect of 71 cases of malignant ascites.Methods 71 patients with malignant ascites who were admitted in our hospital and treated by intracavitary drug infusion from January 2012 to December 2018 were selected as the study subjects.This study was conducted using retrospective cohort analysis.The patients were divided into cisplatin group,cisplatin combined with endostar group and fluorouracil group according to the treatment drugs;the patients were divided into initial treatment group and recurrence group according to the treatment times.Results 12 cases of gastric cancer were treated with cisplatin,and the overall response rate(ORR)was 50%;14 cases of gastric cancer were treated with cisplatin combined with endostar,and the ORR was 57.1%,and the difference was statistically significant(P<0.05);8 cases of ovarian cancer were treated with cisplatin,and the ORR was 62.5%;5 cases of ovarian cancer were treated with cisplatin combined with endostar,and the ORR was 60%,and the difference was not statistically significant(P>0.05);3 cases of lung cancer were treated with cisplatin,and the ORR was 0;6 cases of lung cancer were treated with cisplatin combined with endostar,and the ORR was 16.7%,and the difference was not statistically significant(P>0.05);13 cases of colorectal cancer were treated with fluorouracil,and the ORR was 15.3%,7 cases of pancreatic and biliary cancer were treated with fluorouracil,and the ORR was 0.In the initial treatment group,9 cases were treated with cisplatin,ORR was 66.7%,12 cases were treated with cisplatin and endostar,ORR was 66.7%,and the difference was not statistically significant(P>0.05).In the recurrence group,14 cases were treated with cisplatin,ORR was 35.7%,16 cases were treated with cisplatin and endostar,ORR was 31.2%,and the difference was not statistically significant(P>0.05).In the cisplatin group,the ORR was 66.7%in the initial treatment group,and 35.7%in the recurrence group,and the difference was statistically significant(P<0.05).In

关 键 词：恶性腹腔积液 腔内药物治疗 疗效 回顾性分析 

分 类 号：R730.5[医药卫生—肿瘤]